World's first robot ‘could give birth to human baby'
Experts are developing technology that will mimic a pregnancy from conception to delivery, with the infant growing inside an artificial womb and receiving nutrients through a tube.
After nine months, a live baby will be born, according to Dr Zhang Qifeng, who founded the company Kaiwa Technology, in the city of Guangzhou.
Dr Zhang, a PHD graduate from Nanyang Technological University in Singapore, has claimed the technology is already in a 'mature stage'.
He added: 'Now it needs to be implanted in the robot's abdomen so that a real person and the robot can interact to achieve pregnancy, allowing the fetus to grow inside'.
A prototype of the humanoid is set to be sold for around £10,000 (100,000 yuan) next year.
Reports in the Chinese media said that the humanoid has been designed to mimic the entire process of pregnancy, from the moment of conception to birth.
However, the specifics on exactly how the egg and sperm are fertilised are currently unclear.
For the entire gestation period, the infant will live inside the robot's body, although experts have not yet stated how the foetus will be implanted in the tech womb.
The developing babies will be surrounded by artificial amniotic fluid to create a womb-like environment.
Dr Zhang said the technology is not an entirely new concept, as scientists in the past have successfully kept premature lambs alive inside a 'biobag' for weeks.
The innovation has already prompted a legal and ethical debate. Dr Zhang said he had already been in talks with Guangdong Province authorities to prepare drafts for policy and legislation.
If successful, the science could revolutionise medical science and our notions of family and fertility.
The humanoid could be seen as a tool to tackle rising rates of infertility in China, which has gone up from 11.9 per cent in 2007 to 18 per cent in 2020.
'Problematic' technology
But some critics have condemned the 'problematic' technology, arguing that depriving a foetus of maternal connection is unethical and cruel.
Chinese News outlet The Standard reported that some medical experts are sceptical over the technology's ability to replicate human gestation.
The experts have allegedly stated that complex biological processes, such as maternal hormone secretion, cannot be duplicated by science.
Andrea Dworkin, the radical feminist writer, has previously hit out at artificial womb technology for fears that it would result in 'the end of women'.
Researchers from The Children's Hospital of Philadelphia published an article in 2022 in which they said that such technology might 'pathologise' pregnancy.
However, some argue that artificial wombs could liberate women from pregnancy risks so that they would no longer have to endure the physical burden of carrying a baby.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
26 minutes ago
- CNET
Take Control of Your Google Search Results by Choosing the Sources You Want to See
Facing criticism for degraded search results and angst from users wanting to avoid AI Overviews, Google has announced a new search feature that lets you choose the sites you want to see in your news and search results. Google said in a recent blog post that it's launching Preferred Sources in the US and India this month. The new feature can be accessed through a plus icon to the right of Top Stories panels or a direct link to your preferences. "Once you select your sources, they will appear more frequently in Top Stories or in a dedicated 'From your sources' section on the search results page. You'll still see content from other sites, and can manage your selections at any time," Google said. The new feature is the result of a Labs experiment. Google says that in that version, half of its users added four or more sources. Google offered advice to website publishers and owners on how to direct readers to add their site. How you can select your own preferred sources on Google Search It's simple to add preferred sources for Google Search. You can click the star icon to the right of any "Top Stories" panel in Google Search, which will spawn a pop-up window to add sources, or you can visit the settings page directly at Google has added a preferred sources link next to Top Stories for users in the US and India. Screenshot by Peter Butler/CNET Once you see the search box that says "Search by name or website," type the name or URL of a site you definitely want to include in your search results -- such as CNET or its sibling tech sites ZDNET, Mashable, PCMag and Lifehacker -- then select the checkbox next to each site you want to add. To view and manage your preferred sources, click on the "Your sources" link at the bottom of the preferences page. To remove any of your preferred sources, simply uncheck the checkbox for any sites you want to delete. It's easy to add and remove preferred sources. Screenshot by Peter Butler/CNET You can use any web browser on desktop or mobile to take advantage of Google's new preferred sources feature, but you will need to be signed in to your Google account. What it means for news sites and their readers News organizations and other information sites have shifted before to cater to Google's search algorithm as well as those on other platforms including Facebook and Instagram. Publishers executed a pivot to video in the 2010s, and in recent years produced more bite-sized content suitable for sharing on platforms such as TikTok. Here's how you get to select your news sources. Google The addition of news preferences might be a double-edged sword, giving you more control over search results while further shutting out some legitimate news publishers as new echo chambers get built. "It's almost like a tone-deaf move by Google in my point of view, because news organizations are already concerned about losing traffic to the AI overviews," said Alex Mahadevan, director of MediaWise at Poynter, a nonprofit, nonpartisan media literacy program. "Now they have to figure out how to get people to pick their source in the source preferences." For bigger news publishers who have a loyal audience, Preferred Sources might prove that audience engagement efforts can pay off. But Mahadevan says it will depend on how willing people are to effectively subscribe to and curate their own news sources list. "I question how many people will actually use it," he said. People may see their own beliefs reinforced, not challenged Publishers who haven't cultivated engaged, loyal followers and don't have the means to steer their audiences might suffer, Mahadevan says. "The thing that does concern me about this is you know for the organizations that may have not done that, it's just going to further erode the amount of Google traffic they get," Mahadevan said. "If way more people want news from Fox News and are choosing Fox News among their source preferences, then that's going to be crowding out other news sites that might need that traffic." As an experiment, Mahadevan says he set Breitbart News Network as a source using the Google Search feature, saying he chose the far-right news source because it has been known to share misinformation. "I started Googling about tariffs, and the first thing I see is Breitbart," he said. "So this concerns me also from a media literacy standpoint because I think it might further push people into echo chambers," where they only see beliefs that correspond with those they already hold. "It just seems like a way for people to narrow down their news diet even more via Google Search," Mahadevan said. If SEO, the way that websites have for decades drawn Google traffic by generating good, relevant content, is effectively out the window, what does that mean for the future of publishing and media? "Is there a strong enough media literacy base for people to make sure they're choosing good, legitimate news outlets and a varied variety of news sources?" Mahadevan asked. "I don't know if we're quite there yet."
Washington Post
32 minutes ago
- Washington Post
Japan's SoftBank to take $2 billion stake in computer chip maker Intel
BANGKOK — Japanese technology giant SoftBank Group plans to take a $2 billion stake in computer chip maker Intel as it deepens its involvement in U.S. semiconductor manufacturing and other advanced technology in the United States, the companies said Monday. Shares in SoftBank fell 4% Tuesday in Tokyo following the announcement, which coincided with unconfirmed reports that President Donald Trump is considering having the U.S. government buy a stake in the chip maker.
Yahoo
35 minutes ago
- Yahoo
Coloplast A/S - Interim Financial Report, 9M 2024/25
2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin1,2 was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin1 was 27%, on par with last year2. Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. "We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register hereAccess the conference call webcast directly here: Coloplast - 9M 2024/25 conference call For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkadim@ Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266Email: dkkhu@ Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981Email: dksdk@ Press and mediaPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@ AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenmarkCompany reg. (CVR) no. 69749917 This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_releaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
